Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by 2 October 2015.

Register online, or by phone, fax or mail.  Please indicate that you would like to present a poster.  Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool.  Please see below for more information. 

Reasons you should present your research poster at this conference: 

  • Your research will be seen by our international delegation, representing leaders from
    top pharmaceutical, biotech, academic and government institutions
  • Receive €45 off your registration
  • Your poster abstract will be published in our conference materials


 NOTE: Special poster restrictions. 


 1. Posters will be limited to ONE poster per person.  


 2. You must select the ONE TRACK at which you wish to present your poster. Your poster will hang only for the duration of that track.  (Your poster selection must be concurrent with your registration selection, but it does not have to be the same.)   * If necessary, posters may be reassigned to another session based on attendance.   

 3. Special poster size required:   Posters should be portrait (vertical) orientation, ISO paper size A0: (841 mm wide x 1189 mm high) or (33.11 inches wide × 46.81 inches high).  Maximum board dimensions are (1000 mm wide x 1200 mm high) or (39.37 inches wide × 47.24 inches high).  Oversize posters will not fit.


* CHI reserves the right to publish your poster title and abstract in various marketing materials and products. 

Click here for poster instructions and guidelines 


Partial List of 2015 Poster Titles

  • Academia Sinica - Quantitation of Core-Fucosylation on N-Glycan of the Antibodies
  • Agency for Science, Technology and Research (A*STAR) - Targeting RON for Therapy
  • Anti Doping Laboratory Qatar - Production of Novel Varients of Superantigens for Effecient Cancer Treatment
  • a-star - Enhanced Antigen Detection in Immunohistochemical (IHC) Staining Using a "Digitised" Chimeric Antibody
  • Bio-Rad AbD Serotec GmbH - Recombinant Anti-Idiotypic Antibodies for Antibody Drug Development
  • Bruker UK Ltd - Upstream Quality Control of Therapeutic Antibodies using Automated IdeS Digestion and Subunit Separation in Combination with Ultrahigh-Resolution QTOF MS Analysis
  • CALIXAR - Native Isolation of Functional Ion Channels
  • CALIXAR - Stabilization of Native and Functional Membrane Proteins
  • Chemical Computing Group - Generating Focused Protein and Antibody Libraries for Protein Engineering
  • Chinese University of Hong Kong - Anti-Idiotype scFv for Pharmacokinetics Determination in Phase I/II Clinical Trials
  • CSL Limited - Novel One-Step Cloning Method for Rapid Reformatting of Phage-Displayed Antibody Fragments into Full Length IgGs
  • Development Center for Biotechnology - Application of Single Peripheral Blood B Cells for Fully Human Monoclonal Antibodies Screening
  • Development Center for Biotechnology - Light Chain-Bridged Single Chain Anti-Her2/Anti-CD3 Bi-Specific Antibody for Her2+ Cancer Therapy
  • Development Center for Biotechnology - Pre-Clinical PK-PD Analysis of Anti-HSV mAb in Disease Animals
  • ETH Zurich - Immunocytokines for the Treatment of Ulcerative Colitis
  • FFE Service GmbH - Three Novel Protocols for Protein Purification by Free-Flow-Electrophoresis
  • Fraunhofer IZI-BB - Eukaryotic Lysates for Cell-Free Bioproduction
  • Freeslate, Inc. - Automated High-Throughput Formulation Development of Biologics
  • Garvan Institute of Medical Research - Visualization of DNA and RNA G-quadruplexes in Human Cells Using Highly Specific Antibody Fragments
  • IIB-Sant Pau (Biomedical Research Institute Sant Pau) - Regulatable Self-Assembling of In Vivo Stable Protein Nanoparticles Using Non-Amyloidogenic Peptide Tags
  • Industrial Technology Research Institute - Preclinical Pharmacokinetics Workflow in ITRI
  • IntelliCyt Corporation - High Throughput Cytokine Secretion Assays for Functional Characterization of Checkpoint Inhibitors
  • Jagiellonian University - Highly Stable IgG3-Based Reagent for Typing of B Antigen from ABO Blood Group System
  • JAIST - New Insights of Engineering Expression Systems based on Ultrafast DNA and RNA photocrosslinking
  • Kobe University - C-terminal-Oriented Immobilization of Enzymes Using Sortase A-Mediated Technique
  • Kobe University - Streptavidin Hydrogel as a Scaffold for Protein Assembly
  • KTH Royal Institute of Technology - Development of Affinity Domains for Site Specific Labelling of IgG
  • Lund University - Limited Proteolysis and Quantitative Mass Spectrometry to Define the Stable Core of Protein Complexes
  • MedImmune Ltd. - Ultra-High Content Screening of Cell-Surface-Selected Antibodies in a Complex 3D Tumour Cell Model
  • Merck Sharp & Dohme - Comparison of SAFC Culture Medium Produced at Two SAFC Sites Using a Qualified Small Scale Bioreactor Model
  • MSD - Sizing & Counting of Subvisible Particles by Microflow Imaging and Light Obscuration Compared Including Evalation Particle Morphology Assessment
  • Novo Nordisk A/S - How to Extract Silicone Oil Droplets from the Particle Count
  • Novo Nordisk Pharmatech - Particle Identification by Multi-Technique Methods at Novo Nordisk Pharmatech
  • PhyNexus, Inc. - Fully Automated Mini, Midi, and Maxi Plasmid Prep on the AutoPlasmid MEA Instrument
  • Polyplus-transfection - Improving Productivity in Transient Gene Expression Systems with FectoPROâ„¢, a Novel Powerful Transfection Solution
  • ProteoNic BV - Optimization of 2G UNic Technology for Enhanced Protein Production under GS Selection in CHO-S and CHO GS -/- Cells
  • RIKEN - Secretory Production of Tetrameric Native Full-Length Streptavidin with Thermostability Using Streptomyces Lividans as a Host
  • Roche - Cell Line Development Platform for Asymmetric 2+1 CrossMAb Bispecific Antibodies
  • SBU - Pichia Pastoris Heterologous Expression of Trichoderma Reesei Cellobiohydrolase I with Modified- Glycosylation Sites
  • Solve Research and Consultancy - Size Characterization of Proteins and Nanoparticles
  • Technical University Of Denmark - Engineering the CHO Cell
  • TSI, Inc. - Investigating Protein Fragments and Aggregates as Well as Protein-Protein Interactions using Macroion Mobility Spectrometry
  • UCL - A Plug-and-Play Approach to Antibody-Based Therapeutics via a Chemoselective Dual Click Strategy
  • University Autonoma De Barcelona - Impact of Protein Building Blocks Downstream Strategy on the Architecture and Biological Performance of Cell-Targeted Protein Nanoparticles
  • University of Aveiro - Aqueous Biphasic Systems Composed of Cholinium-Based Ionic Liquids for the Extraction of Immunoglobulin Y, IgY, from Egg Yolk
  • University of BorÃ¥s - Textile Bioreactor for Ethanol Production
  • University of Queensland - Monoclonal Antibodies Against Canine Cell Surface Receptor c-Kit, Isolated from a Phage Display Library Using Whole Cell Panning
  • University of Tampere - Highly Stable Chimeric Avidin
  • University of Tuebingen - Development of Recombinant Bispecific Antibodies for Selective Stimulation of the CD95 Death Receptor on Activated B Cells and Lymphoma Cells
  • University of Zurich - Engineering Proteins for Cytosolic Delivery
  • University of Zurich - Establishment of an Innovative High-Throughput Platform for Next-Generation Binder Discovery
  • Vaccinex Inc. - Antibody Library Display on a Mammalian Virus: Combining the Advantages of Panning and Cell Sorting in One Technology
  • VTT Technical Research Centre of Finland - Next Generation Biotherapeutic Production System: The Filamentous Fungus Trichoderma Reesei
  • Waters Corporation - Complementary HILIC-Based Separations for the Characterization and Analysis of Erythropoetin